Are generic topical prostanoids the way forward in the care of glaucoma patients? – No

Dubois, V.

doi:10.1038/eye.2013.129

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also important to consider the possibility that cheaper medication costs may not automatically translate to cheaper overall costs. Dubois summarised several scenarios where use of generic eye drops may not automatically lead to a cost saving [24]. For example, if the switch to a generic leads to reduced adherence due to difficulty using a new bottle design, if the patient beings running out of medication early due to the generic bottle dispensing too large volume of medication, or if a difference in inactive ingredients leads to a higher rate of ocular surface disease.…”

Section: Costsmentioning

confidence: 99%

The Use of Generic Medications for Glaucoma

Tatham

2020

Journal of Ophthalmology

View full text Add to dashboard Cite

The use of generic medicines has grown considerably in recent years providing considerable cost savings. In England, generic items represented 11.7% of prescriptions for glaucoma and ocular hypertension in 2009, increasing to 55.2% of prescriptions in 2018. Generics can be brought to the market quickly and at low cost as manufacturers are not required to repeat animal or clinical research on active ingredients already approved for safety and efficacy. Although there is no regulatory requirement for studies comparing branded and generic eye drops, several randomised crossover studies have been performed comparing branded and generic prostaglandin analogues. While most have shown similar intraocular pressure lowering, studies are of short duration and have not evaluated visual field endpoints. Furthermore, differences in inactive ingredients, pH, viscosity, levels of particulate matter, and degradation over time have been reported. Other potential problems with generic eye drops include differences in bottle design affecting adherence, problems with supply, and the possibility that reduced revenue for innovator companies will lead to reduced investment in new drug development. This article reviews the potential advantages and disadvantages of generic antiglaucoma medications.

show abstract

Section: Costsmentioning

confidence: 99%

The Use of Generic Medications for Glaucoma

Tatham

2020

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The US patent for Xalatan expired in March 2011 and since then generic formulations of latanoprost have been available. While it is acknowledged these are cost-effective,6 FDA regulations do not dictate dropper design or rigidity and hence some patients may find these generics difficult to use, affecting compliance and therefore treatment efficacy 7…”

Section: Introductionmentioning

confidence: 99%

Usability of prostaglandin monotherapy eye droppers

Drew

Wolffsohn

2015

Br J Ophthalmol

View full text Add to dashboard Cite

Subtitle:The force required to expel a drop differs between Prostaglandin monotherapy dropper designs and some exceeded the maximum force that could be comfortably applied by around half the population, which may affect compliance and efficacy. 2 ABSTRACTAim: To determine the force needed to extract a drop from a range of current prostaglandin monotherapy eye droppers and how this related to the comfortable and maximum pressure subjects could exert. Methods:The comfortable and maximum pressure subjects could apply to an eye dropper constructed around a set of cantilevered pressure sensors and mounted above their eye was assessed in 102 subjects (mean 51.2±18.7 years), repeated 3 times. A load cell amplifier, mounted on a stepper motor controlled linear slide, was constructed and calibrated to test the force required to extract the first 3 drops from 13 multi-dose or uni-dose latanoprost medication eye droppers. Results:The pressure that could be exerted on a dropper comfortably Conclusions:Prostaglandin monotherapy droppers for glaucoma treatment vary in their resistance to extract a drop and with some a drop could not be comfortably achieved by half the population, which may affect compliance and efficacy.3

show abstract

“…1,2 We prospectively studied our patients' experience and the impact of generic use on our population. We also investigated the potency of generics versus Xalatan.…”

Section: Sir Patient Experience Of the Transition From Xalatan To Gementioning

confidence: 99%